PBI 06150
Alternative Names: PBI-06150Latest Information Update: 28 Apr 2025
At a glance
- Originator Phoenix Biotechnology
- Developer Phoenix Biotechnology; Texas Biomedical Research Institute; University of Texas Medical Branch
- Class Antivirals; Cardiac glycosides; Polyphenols
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (Sublingual)
- 17 Mar 2021 Preclinical trials in COVID-2019 infections in USA (Sublingual)
- 17 Mar 2021 Antimicrobial and adverse events data from preclinical studies in COVID-2019 infections released by Phoenix Biotechnology